Omega-3 Fish Oil for Nonalcoholic Steatohepatitis

Omega-3 鱼油治疗非酒精性脂肪性肝炎

• 批准号: 7094666
• 负责人: STEPHEN H CALDWELL
• 金额: $ 17.9万
• 依托单位: UNIVERSITY OF VIRGINIA
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-09-01 至 2009-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7094666
• 关键词: clinical research; diet; exercise; exercise tolerance; fats; fatty acids; human; injury; insulin sensitivity /resistance; lifestyle; lipids; liver; marine animal oil; measurement; omega 3 fatty acid; reduction; weight loss

DESCRIPTION (provided by applicant): Nonalcoholic steatohepatitis (NASH) occurs in 2-3% of the US population and carries a 15-20% chance of progression to cirrhosis. It is closely associated with obesity, hyperlipidemia and insulin resistance. Therapy usually includes recommendations to increase exercise and to begin weight reducing diets but these goals are variably achieved and their relative effects in conjunction with pharmacological intervention have not been well-defined. Other forms of therapy include insulin sensitizing agents but no intervention is proven or uniformly accepted. Furthermore, interpretation of pharmacological treatment results is confounded by commonly recommended life-style changes voluntarily adopted by the patient. Polyunsaturated fatty acids, especially formulations rich in omega-3 fatty, are widely accepted and endorsed in the medical community for their beneficial effects on hyperlipidemia and coronary disease risk reduction. Recent data suggests that omega 3 fatty acids ameliorate hepatic steatosis in humans and in animal models of NASH by reducing hepatic fat content. We hypothesize that omega-3 fatty acid (3g/day) will produce improvement in NASH activity, liver fat content, and lipid profiles independent of weight loss or exercise conditioning compared to a placebo. Among commonly used supplements, omega-3 rich fish oils stand out as having won endorsement from the American Heart Association and FDA approval for a qualified health claim in coronary risk reduction. We have chosen a brand of omega-3 that exceeds purity marks set by European and Scandanavian Medicinal Standards and meets recently adopted criteria set by NCCAM. Our primary endpoint is to assess changes in a composite score of NASH-induced liver injury relative to changes in exercise tolerance and weight. Other secondary endpoints include changes in liver fat content by MRI, blood lipid profile, insulin sensitivity and markers of the metabolic syndrome after treatment. Statistical analysis will be performed to assess the impact of weight loss and changes in exercise tolerance on the primary endpoint relative to omega-3 use. This GCRC-based pilot study of 50 evaluable subjects will establish a workable platform for multicenter trials to measure the relative impact of voluntary life-style modification on potentially effective pharmacological therapy in treating NASH.

描述(由申请人提供)：非酒精性脂肪性肝炎(NASH)发生在2-3%的美国人口中，并有15%-20%的机会进展为肝硬变。它与肥胖、高脂血症和胰岛素抵抗密切相关。治疗通常包括建议增加锻炼和开始减肥饮食，但这些目标是可变地实现的，它们与药物干预相结合的相对效果尚未得到很好的定义。其他形式的治疗包括胰岛素增敏剂，但没有任何干预措施得到证实或统一接受。此外，对药物治疗结果的解释被患者自愿采用的普遍推荐的生活方式改变所混淆。多不饱和脂肪酸，特别是富含omega-3脂肪的制剂，因其对高脂血症和降低冠心病风险的有益作用而被医学界广泛接受和认可。最近的数据表明，omega 3脂肪酸通过降低肝脏脂肪含量来改善人类和NASH动物模型的肝脏脂肪变性。我们假设，与安慰剂相比，与安慰剂相比，omega-3脂肪酸(3g/天)将在NASH活性、肝脏脂肪含量和脂类分布方面产生改善，而与减肥或运动条件无关。在常用的补充剂中，富含omega-3的鱼油脱颖而出，获得了美国心脏协会和FDA的批准，在降低冠状动脉风险方面获得了合格的健康声明。我们选择了一个品牌的omega-3，其纯度超过了欧洲和斯堪的纳维亚药品标准设定的标准，并符合NCCAM最近制定的标准。我们的主要终点是评估NASH诱导的肝损伤的综合评分相对于运动耐量和体重变化的变化。其他次要终点包括治疗后MRI肝脏脂肪含量、血脂谱、胰岛素敏感性和代谢综合征标志物的变化。将进行统计分析，以评估体重减轻和运动耐量变化对相对于omega-3使用的主要终点的影响。这项基于GCRC的50名可评估受试者的初步研究将为多中心试验建立一个可行的平台，以衡量自愿改变生活方式对治疗NASH的潜在有效药物疗法的相对影响。